HEPARIN SODIUM Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Heparin Sodium, and what generic alternatives are available?
Heparin Sodium is a drug marketed by Abraxis Pharm, Aspen Global Inc, B Braun Medical Inc, Be Pharms, Casi Pharms Inc, Chamberlin Parenterl, Dell Labs, Dr Reddys, Epic Pharma Llc, Fresenius Kabi Usa, Gland, Hikma, Hospira, Hospira Inc, Lilly, Luitpold, Mylan Labs Ltd, Nanjing King-friend, Parke Davis, Pfizer, Pharm Spec, Pharmacia And Upjohn, Sagent Pharms, Sandoz, Shenzhen Techdow, Smith And Nephew, Solopak, Watson Labs Inc, Baxter Hlthcare, Mcgaw, B Braun, and Pharma Serve Ny. and is included in sixty-nine NDAs.
The generic ingredient in HEPARIN SODIUM is heparin sodium. There are seventy-seven drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the heparin sodium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Heparin Sodium
A generic version of HEPARIN SODIUM was approved as heparin sodium by HOSPIRA on April 28th, 1983.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for HEPARIN SODIUM?
- What are the global sales for HEPARIN SODIUM?
- What is Average Wholesale Price for HEPARIN SODIUM?
Summary for HEPARIN SODIUM
| US Patents: | 0 |
| Applicants: | 32 |
| NDAs: | 69 |
| Finished Product Suppliers / Packagers: | 20 |
| Clinical Trials: | 98 |
| Drug Prices: | Drug price information for HEPARIN SODIUM |
| What excipients (inactive ingredients) are in HEPARIN SODIUM? | HEPARIN SODIUM excipients list |
| DailyMed Link: | HEPARIN SODIUM at DailyMed |
Recent Clinical Trials for HEPARIN SODIUM
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Vaneltix Pharma, Inc. | Phase 2 |
| Prevail Infoworks, Inc | Phase 2 |
| The First Affiliated Hospital with Nanjing Medical University | N/A |
Pharmacology for HEPARIN SODIUM
| Drug Class | Anti-coagulant Unfractionated Heparin |
Anatomical Therapeutic Chemical (ATC) Classes for HEPARIN SODIUM
US Patents and Regulatory Information for HEPARIN SODIUM
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mylan Labs Ltd | HEPARIN SODIUM | heparin sodium | INJECTABLE;INJECTION | 203851-002 | Nov 30, 2017 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Sandoz | HEPARIN SODIUM | heparin sodium | INJECTABLE;INJECTION | 091682-001 | Jun 8, 2011 | AP | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Fresenius Kabi Usa | HEPARIN SODIUM | heparin sodium | INJECTABLE;INJECTION | 017651-006 | Approved Prior to Jan 1, 1982 | AP | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Epic Pharma Llc | HEPARIN SODIUM | heparin sodium | INJECTABLE;INJECTION | 017486-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Mcgaw | HEPARIN SODIUM 5,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER | heparin sodium | INJECTABLE;INJECTION | 019130-002 | Dec 31, 1984 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Fresenius Kabi Usa | HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% | heparin sodium | INJECTABLE;INJECTION | 017029-025 | Aug 24, 2017 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
